Allegiance Equity Corporation Shareholder Update

TORONTO, Sept. 26, 2011 /CNW/ - Allegiance Equity Corporation (TSXV: ANQ.V) ( is pleased to provide a shareholder update.

Update on  RELIEVA(TM) and Clinical Trials with DSE Healthcare Solutions L.L.C.

DSE Healthcare Solutions L.L.C., Edison, New Jersey is in the final stages of its clinical trial with a new formulation for Relieva.

The clinical trial with the new formulation will be completed shortly where all expenses were assumed by DSE Healthcare. DSE Healthcare Solutions is successful in the marketing of health care, medical and consumer products to mass food and drug market. DSE Healthcare Solutions was founded by very experienced former managers of one of the world's largest pharmaceutical and health care companies. Robert C. Stites, the CEO and one of the founders of DSE, was previously President and Chief Operating Officer of Johnson & Johnson Products.

Allegiance is also in discussions with a number of companies including two multinationals for licensing Relieva, one of which is one of the largest consumer goods companies in the world and the other a Spanish Pharmaceutical Company. These companies have been testing and experimenting as part of their due diligence with Relieva and Psoberine extract

Relieva(TM) made with Psorberine(TM) an anti-inflammatory, antibacterial product for the treatment of psoriasis and atopic dermatitis. Relieva(TM) provides immediate relief for itching, irritation and inflammation associated with almost all problem skin conditions with ZERO toxicity and Irritation.

Relieva is a premium skin care product for everyday use for healthy skin. However that is only half the story. Relieva and Psorberine have a number of significant distinct competitive advantages over existing psoriasis treatments including the world's largest selling psoriasis treatment. Other psoriasis treatments (including the leader) may lose their effectiveness over time as the disease builds up tolerability to other treatments this is not the case with Relieva that has a zero irritancy and toxicity rating, with no known health risks or side effects.

Global Psoriasis Drugs Market to Exceed $7.3 Billion Dollars by 2015, according to new reports by "Global Industry analysts Inc." with no satisfactory treatment in sight

Allegiance Equity and Fernando Pisano from  Simcoe Asia Group (SA Group) 

Fernando Pisano CEO of SA Group commented,"SA Group is excited to represent Allegiance's outstanding products. Relieva Psoriasis cream has over 4 million dollars of research behind it and is one of the best OTC products available to the public. CinGx is a new and outstanding ingredient for food products targeting diabetes sufferers that could revolutionize the food industry, like Stevia and Aspartame have. We expect to see them as an additive to many existing product lines and many new ones".

Pisano further noted that, "With over 366 million people living with diabetes and over 125 million people living with Psoriasis, and almost that many with other skin ailments like Eczema rashes and skin allergies, Allegiance's products address a very large market that we look forward to penetrating." 

"This alliance will be beneficial to Allegiance in many ways," stated David Solomon, President of Allegiance Equity. "The marketing and licensing abilities of SA Group are impressive, not to mention their abilities to introduce potential joint ventures and endorsements that will add to the marketing efforts on a global scale," concluded David Solomon. 

"Allegiance Equity is extremely fortunate to have such strong partners as Nealanders and SA Group, which is a testimony to the quality of the Company's products and validates the growing demand for these products," commented David Solomon

Allegiance Terminates Agreement with Premier Selling Technologies Inc (Premier)

Allegiance has terminated its agreement dated May 2nd 2011 with Premier previously announced on May 3rd 2011 as a result of Premier`s breach of contract and its failure to meet its obligations hereunder


Allegiance  previously announced a proposed private a private placement to raise up to $250,000 by sale of common shares to be priced within the context of the market on August 26th ,2011 and will not proceed withthis placement However Allegiance will proceed and close a private placement to be priced wiyhin the context of the market within the next 15 days.

Interest of Management Notice of Intention to Distribute

Palm American Investments Inc. is the controlling shareholder of Allegiance holding 1,867,831 common 1, shares. Palm American Investment Inc is controlled by David Solomon, Marilyn Bloovol and members of their family, Corporations controlled by Marilyn Bloovol and David Solomon, directors and officers of Allegiance may participate in the private placement, directly or indirectly through corporations controlled by them. Palm American filed a Notice of Intention on September 20th to sell up to 500,000 common shares in the market from time to time or by way of private sale


Allegiance targets billion dollar markets having clearly identified product deficiencies and dissatisfied patients who suffer widespread diseases and conditions including diabetes, cholesterol, Alzheimer`s and Dementia and arthritis.

Allegiance's strategy utilizes leading-edge scientific technology to create valuable, proprietary and effective natural treatments, recognized as safe and effective by North American regulatory authorities, at a fraction of the cost and time it takes to develop a prescription drug. Allegiance then obtains patents and regulatory approvals.

There are presently 7,061921 common shares of Allegiance issued and outstanding.

Additional information relevant to the Company's activities, including the Company's press releases can found on SEDAR at

The TSX Venture Exchange has not reviewed and does not accept responsibility FOR THE ADEQUACY OR ACCURACY FOR HIS PRESS RELEASE, WHICH HAS BEEN PREPARED BY MANAGEMENT.

SOURCE Allegiance Equity Corporation

For further information:

on Allegiance Equity Corporation, contact David Solomon, President, by telephone at (416) 630 1221 or (647) 271-7208, or

Profil de l'entreprise

Allegiance Equity Corporation

Renseignements sur cet organisme


Jetez un coup d’œil sur nos forfaits personnalisés ou créez le vôtre selon vos besoins de communication particuliers.

Commencez dès aujourd'hui .


Remplissez un formulaire d'adhésion à CNW ou communiquez avec nous au 1-877-269-7890.


Demandez plus d'informations sur les produits et services de CNW ou communiquez avec nous au 1‑877-269-7890.